Although the different co-players and targets of USP8 may in part vary in different cell lines, the preclinical results reported here, together with our translation study in clinical specimens is in keeping with the recent literature showing a role for USP8 in cancer progression and increased USP8 in patients resistant to neoadjuvant therapies (Xie et al., 2022) and highlight promising features of USP8 as a possible ovarian carcinoma biomarker. The gene discussed is USP8; the disease is cancer.